In addition, Antonarakis et al. [57] in real-world individuals with advanced prostate cancer showed that both PSA and ctDNA were additive and independent prognostic factors, prompting a greater benefit from evaluation of both in tandem beyond genomic profiling. The gene discussed is KLK3; the disease is prostate carcinoma.